Gemcitabine: Efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 177-184

  Hayashi, Hidetoshi ^a   Kurata, Takayasu ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Histology elderly patients; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; PYRIMIDINE NUCLEOSIDE;

ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84860407228     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6252     Document Type: Review

References (34)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
2. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of doc-etaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004;22:254-61.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92-8.
4. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of pacli-taxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-8.
5. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difuoro-2'-deoxycytidine). Cancer Res. 1990;50:4417-2.
6. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17 Suppl 5:v7-12.
7. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-8.
8. Csoka K, Liliemark J, Larsson R, et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hemato-logic or solid tumors. Semin Oncol. 1995;22:47-53.
9. Von Hoff DD. Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Invest New Drugs. 1996;14:265-70.
10. 2) levels. Invest New Drugs. 1997;15:115-21.
11. Abratt RP, Sandler A, Crino L, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: infuence of scheduling on toxicity and drug delivery. Semin Oncol. 1998;25:35-43.
12. Rinaldi M, Crino L, Scagliotti GV, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol. 2000;11: 1295-300.
13. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12-8.
14. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-30.
15. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as frst-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27: 1227-34.
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with beva-cizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
17. Maemondo M, Inoue A, Kobayashi K, et al. Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362: 2380-8.
18. Mitsudomi T, Morita S, Yatabe Y, et al. Geftinib versus cisplatin plus doc-etaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121-8.
19. Hirsch FR, Spreafco A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468-81.
20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cispla-tin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
21. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005;47:69-80.
22. Hoang T, Dahlberg S, Johnson JSD. Does Histology Predict Survival of Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Standard Platin-Based Chemotherapy? S493, abstr PD6.4.1. J Thorac Oncol. 2009.
23. Scagliotti G V, De Marinis F, Rinaldi M, et al. The role of histology with common frst-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol. 2009;4:1568-71.
24. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 2008. 14:4206-12.
25. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced nons-mall cell lung cancer (NSCLC). Abstract P#6521, The European Cancer Conference 2007 (ECCO 14). Eur J Cancer. 2007;5:363.
26. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-40.
27. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-91.
28. Gridelli C, Ciardiello R, Feld R, et al. International multicenter randomized phase III study of frst-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus frst-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial (abstract #7508). J Clin Oncol. 2010;28:540s.
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
30. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33:2313-4.
31. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999;91:66-72.
32. Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:1029-30; author reply 1030-1.
33. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72.
34. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).(abstract #0002). J Clin Oncol. 2010;28:946s.